| CG43 |
Obesity (CG43) |
|
-
-
diet
Fast, easy summary view of NICE guidance on 'diet'
-
-
-
Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children
The NICE clinical guideline on the prevention, identification, assessment and management of overweight and obesity in adults and children covers:
- how staff in GP surgeries and hospitals should assess whether people are overweight or obese
- what staff in GP surgeries and hospitals should do to help people lose weight
- care for people whose weight puts their health at risk.
- how people can make sure they and their children stay at a healthy weight
- how health professionals, local authorities and communities, childcare providers, schools and employers should make it easier for people to improve their diet and become more active.
Responsibility for undertaking a review of this guidance at the designated review date has passed to the National Clinical Guidelines Centre for Acute and Chronic Conditions (NCGCACC). The National Collaborating Centre for Primary Care is no longer active.
Amendment to Understanding NICE Guidance documents
The Understanding NICE Guidance (UNG) versions 'Preventing obesity and staying a healthy weight' and 'Treatment for people who are overweight or obese' previously referred to The Obesity Awareness and Solutions Trust (TOAST) as a source of additional information and support for people wanting to stay a healthy weight or to lose weight. Please note that this organisation closed in December 2007 and is no longer able to provide such information and support, and so reference to the organisation has been removed. The remaining organisations listed in the UNG documents are still able to offer information about preventing or treating obesity.
CG43 Obesity replaces the following pieces of guidance:
Sibutramine (Reductil): marketing authorisation suspended
On 21 January 2010, the MHRA announced the suspension of the marketing authorisation for the obesity drug sibutramine (Reductil). This follows a review by the European Medicines Agency which found that the cardiovascular risks of sibutramine outweigh its benefits. Emerging evidence suggests that there is an increased risk of non-fatal heart attacks and strokes with this medicine.
The MHRA advises that:
- Prescribers should not issue any new prescriptions for sibutramine (Reductil) and should review the treatment of patients taking the drug.
- Pharmacists should stop dispensing Reductil and should advise patients to make an appointment to see their doctor at the next convenient time.
- People who are currently taking Reductil should make a routine appointment with their doctor to discuss alternative measures to lose weight, including use of diet and exercise regimens. Patients may stop treatment before their appointment if they wish.
NICE clinical guideline 43 recommended sibutramine for the treatment of obesity in certain circumstances. These recommendations have now been withdrawn and healthcare professionals should follow the MHRA advice.
-
Other information
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: diet | physical activity
How this guidance was produced
Background information
This page was last updated: 30 May 2012
-
Guideline formats
- Web format
- Quick reference guide
- NICE Guideline (PDF)
- Full Guideline
- CG43 Atal gordewdra a chynnal pwysau iach: (non NHS) deall canllawiau NICE (fformat MS Word)
Obesity
Information for the public
-
Implementation tools and resources
- Audit support
- Baseline assessment tool
- Costing report
- Costing template
- Guide to resources
- Slide set
- CMG45: Integrated commissioning for the prevention of cardiovascular disease
- Obesity: presenter slides
- Bariatric surgical service commissioning guide
- Obesity: online educational tool
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guideline
The published NICE clinical guideline, contains the recommendations for health professionals and NHS bodies.
Full Guideline
The published full clinical guideline for specialists with background, evidence, recommendations and methods used.